Merck has received FDA approval for Lipfendra, the first oral PCSK9 inhibitor for lowering LDL cholesterol, marking a significant advancement in cholesterol treatment. This approval positions Merck for substantial growth in a large market, while posing a competitive threat to existing injectable PCSK9 inhibitor manufacturers.
Merck's Lipfendra, an oral PCSK9 inhibitor, received FDA approval on July 16, 2026, for lowering LDL cholesterol. This is a significant event because it offers a convenient pill alternative to existing injectable PCSK9 inhibitors, potentially expanding the market to millions of patients who are resistant to needles or cannot tolerate statins. This development is a major growth opportunity for Merck, especially as its blockbuster cancer drug Keytruda faces patent expiration. Conversely, it presents a substantial competitive threat to Amgen (Repatha) and Regeneron/Sanofi (Praluent), who currently dominate the PCSK9 inhibitor market with injectable options. The lower price point of Lipfendra also adds pressure on incumbents. Short-term, Merck could see increased investor interest, while long-term, its market share in the cholesterol treatment space is poised for significant expansion. The key risk for traders is the ongoing cardiovascular outcomes trial for Lipfendra, as its approval was based solely on LDL reduction, not yet on proven prevention of heart attacks and strokes.